LobbyingFairmount Funds Management lobbying by quarter
Fairmount Funds Management's latest lobbying report covers Q2 2026, at $80K. The four quarters Q4 2025–Q3 2026 total $240K. Its first report covers Q4 2025; the issues it reports most are Health Issues.
Fairmount Funds Management
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $240K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2025 | $80K | 1 |
| Q1 2026 | $80K | 1 |
| Q2 2026 | $80K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$240K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES3 reports
- SENATE3 reports
Firms it paid
| Firm | ||
|---|---|---|
| BGR Government Affairs | $240K | 3 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| BRENT ALAN DEL MONTE | Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee | Q2 2026 |
| JOHN STONE | Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C | Q2 2026 |
| REMY LEIGH BRIM MASON | Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | BGR Government Affairs | $80K |
| 04/20for Q1 | BGR Government Affairs | $80K |
| 01/20for Q4 2025 | BGR Government Affairs | $80K |
| 25/12/17for Q4 2025 | BGR Government Affairs | Under $5,000 |